Smith & Nephew’s Role in the FTSE 100 Healthcare Segment

Highlights

• Smith & Nephew plc (LON:SN) operates within the healthcare sector under the FTSE 100

• The company is known for orthopaedics, sports medicine, and wound management

• Its operations span globally, with focus on innovation across surgical technologies

Smith & Nephew plc (LON:SN) is part of the healthcare industry and is listed on the FTSE 100, one of the principal indices representing large-cap companies in the United Kingdom. The business focuses on medical devices and technologies, delivering solutions in orthopaedics, advanced wound management, and sports medicine. Its footprint is global, catering to a wide range of medical institutions and professionals.

Orthopaedics Business Segment

Smith & Nephew’s orthopaedics division includes products used in joint reconstruction and trauma. This area includes implants for hips and knees, alongside products used in the treatment of fractures. The unit is structured to support procedural efficiency in both hospital and ambulatory surgical center settings. It maintains a range of surgical systems to assist healthcare providers in delivering consistent patient outcomes.

Sports Medicine and ENT

In sports medicine, the company focuses on minimally invasive surgical technologies used in joint repair, primarily shoulders and knees. It also includes the ear, nose, and throat (ENT) division. These solutions are aimed at restoring mobility through surgical repairs and reconstruction. The focus remains on arthroscopy technologies, enabling treatment through small incisions, supported by imaging and handheld surgical instruments.

Advanced Wound Management

The advanced wound management portfolio delivers products for the treatment of both acute and chronic wounds. This segment includes dressings designed for moisture management, infection prevention, and tissue regeneration. The range supports different wound types, including surgical, traumatic, and diabetic foot ulcers. It includes negative pressure wound therapy and advanced dressings that integrate with digital platforms for remote monitoring.

Geographic Operations and Manufacturing Footprint

Smith & Nephew operates manufacturing sites and innovation centers across multiple continents. Its products are distributed in North America, Europe, Asia, and Latin America. Each location supports different parts of the portfolio, ensuring efficiency in production and logistics. A core focus is also placed on sustainability practices within manufacturing.

Product Innovation and Digital Integration

The company continues to in technology for robotic-assisted surgery and digital connectivity. These developments are part of its efforts to streamline surgical procedures, enhance precision, and improve clinical workflows. The inclusion of AI-driven platforms for data is designed to support clinical decisions and surgical planning.

Presence in Dividend Segment

Smith & Nephew is part of the FTSE Dividend Stocks, representing companies that distribute returns to shareholders. This inclusion reflects consistent dividend activity over time, with the business structured to balance returns and in innovation. The company’s approach emphasizes long-term value generation while maintaining capital discipline.

Regulatory and Clinical Compliance

The business complies with international health and safety regulations. Its research and development units coordinate with regulatory agencies to secure approvals for new devices. Documentation, clinical testing, and surveillance are core to the product lifecycle, ensuring adherence to safety standards.

Global Partnerships and Hospital Networks

Smith & Nephew maintains collaborations with hospitals, research institutions, and healthcare providers. These partnerships support co-development initiatives and clinical education. Through these collaborations, the company expands training and support for surgeons and healthcare professionals using its technologies.

Sector Role and Index Representation

As a member of the FTSE 100, Smith & Nephew reflects the presence of the healthcare sector within the broader UK equities landscape. Its performance influences movements in the index, given its market capitalization and sector weight. Additionally, it plays a role in the healthcare composition of other related benchmarks, including segments of the FTSE 350.